# OnCo record galleri (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/galleri/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "galleri" ;
  schema:name "Galleri"@en ;
  schema:description "GRAIL's blood test that looks for a signal from more than 50 cancers at once; an FDA advisory panel voted in its favour in September 2026, but in the NHS-Galleri randomised trial three yearly tests did not reduce the number of cancers found at a late stage."@en ;
  schema:url <https://onco.cc/drugs/galleri/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://grail.com/press-releases/fda-advisory-committee-votes-in-favor-of-approval-of-grails-galleri-multi-cancer-early-detection-test/>, <https://doi.org/10.1056/NEJMoa2505723>, <https://www.congress.gov/119/plaws/publ75/PLAW-119publ75.htm>, <https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/>, <https://doi.org/10.1038/s41591-026-04652-8> ;
  onco:status "phase-3" ;
  onco:tag "test", "mced", "evidence:no-benefit" ;
  onco:modality "Multi-cancer early detection blood test" ;
  onco:related <https://onco.cc/drugs/shield-mcd/>, <https://onco.cc/drugs/cancerguard/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/mced/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/cfdna-methylation-testing/> ;
  onco:companies <https://onco.cc/companies/grail/> ;
  onco:trials <https://onco.cc/trials/nhs-galleri/>, <https://onco.cc/trials/pathfinder-2/>, <https://onco.cc/trials/pathfinder/>, <https://onco.cc/trials/ccga/>, <https://onco.cc/trials/strive-grail/>, <https://onco.cc/trials/reflection-galleri/>, <https://onco.cc/trials/reach-galleri-medicare/>, <https://onco.cc/trials/galleri-community-research-program/>, <https://onco.cc/trials/galleri-unintentional-weight-loss/>, <https://onco.cc/trials/inform-galleri/>, <https://onco.cc/trials/sentinel-galleri-veterans/>, <https://onco.cc/trials/discover-galleri-symptomatic/>, <https://onco.cc/trials/oc-lead/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nhs-galleri-primary-nejm-2026/>, <https://onco.cc/key-papers/paper-nhs-galleri-performance-nat-med-2026/>, <https://onco.cc/key-papers/paper-pathfinder-2-nat-med-2026/>, <https://onco.cc/key-papers/paper-pathfinder-lancet-2023/>, <https://onco.cc/key-papers/paper-nhs-galleri-design-cancers-2022/>, <https://onco.cc/key-papers/paper-klein-ccga3-mced-validation-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-liu-ccga2-methylation-ann-oncol-2020/>, <https://onco.cc/key-papers/paper-symplify-lancet-oncol-2023/>, <https://onco.cc/key-papers/paper-galleri-real-world-nat-commun-2025/> .